Johnson Charlotte E, Hunt David K, Wiltshire Marie, Herbert Terry P, Sampson Julian R, Errington Rachel J, Davies D Mark, Tee Andrew R
Institute of Cancer and Genetics, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.
Department of Cell Physiology and Pharmacology, University of Leicester, The Henry Wellcome Building, University Road, Leicester LE1 9HN, UK.
Mol Oncol. 2015 Mar;9(3):675-88. doi: 10.1016/j.molonc.2014.11.005. Epub 2014 Nov 22.
Inappropriate activation of mammalian/mechanistic target of rapamycin complex 1 (mTORC1) is common in cancer and has many cellular consequences including elevated endoplasmic reticulum (ER) stress. Cells employ autophagy as a critical compensatory survival mechanism during ER stress. This study utilised drug-induced ER stress through nelfinavir in order to examine ER stress tolerance in cell lines with hyper-active mTORC1 signalling. Our initial findings in wild type cells showed nelfinavir inhibited mTORC1 signalling and upregulated autophagy, as determined by decreased rpS6 and S6K1 phosphorylation, and SQTSM1 protein expression, respectively. Contrastingly, cells with hyper-active mTORC1 displayed basally elevated levels of ER stress which was greatly exaggerated following nelfinavir treatment, seen through increased CHOP mRNA and XBP1 splicing. To further enhance the effects of nelfinavir, we introduced chloroquine as an autophagy inhibitor. Combination of nelfinavir and chloroquine significantly increased ER stress and caused selective cell death in multiple cell line models with hyper-active mTORC1, whilst control cells with normalised mTORC1 signalling tolerated treatment. By comparing chloroquine to other autophagy inhibitors, we uncovered that selective toxicity invoked by chloroquine was independent of autophagy inhibition yet entrapment of chloroquine to acidified lysosomal/endosomal compartments was necessary for cytotoxicity. Our research demonstrates that combination of nelfinavir and chloroquine has therapeutic potential for treatment of mTORC1-driven tumours.
哺乳动物雷帕霉素靶蛋白复合物1(mTORC1)的不适当激活在癌症中很常见,并具有许多细胞后果,包括内质网(ER)应激升高。细胞在ER应激期间利用自噬作为关键的代偿性生存机制。本研究通过奈非那韦诱导药物性ER应激,以检查mTORC1信号过度活跃的细胞系中的ER应激耐受性。我们在野生型细胞中的初步发现表明,奈非那韦抑制mTORC1信号并上调自噬,分别通过rpS6和S6K1磷酸化减少以及SQTSM1蛋白表达来确定。相反,mTORC1过度活跃的细胞显示基础ER应激水平升高,在奈非那韦治疗后大大加剧,通过CHOP mRNA增加和XBP1剪接可见。为了进一步增强奈非那韦的作用,我们引入氯喹作为自噬抑制剂。奈非那韦和氯喹的组合显著增加ER应激,并在多个mTORC1过度活跃的细胞系模型中导致选择性细胞死亡,而mTORC1信号正常化的对照细胞耐受治疗。通过将氯喹与其他自噬抑制剂进行比较,我们发现氯喹引起的选择性毒性与自噬抑制无关,但氯喹被困在酸化的溶酶体/内体隔室中是细胞毒性所必需的。我们的研究表明,奈非那韦和氯喹的组合对治疗mTORC1驱动的肿瘤具有治疗潜力。